Antibodies to alpha-synuclein and uses thereof
AssigneeBristol-Myers Squibb Company
InventorsMichael K. Ahlijanian, Jere Ernest Meredith, Jr., Nino Devidze, John David Graef, Edward L. Halk
Life of this patent
Estimating the term…
Abstract
Disclosed herein are anti-α-synuclein antibodies which preferentially bind to oligomeric α-synuclein over monomeric α-synuclein, therapeutic compositions comprising the antibodies, and methods of using the antibodies to treat synucleinopathies.
Claims28
An isolated antibody comprising:
- a heavy chain variable region comprising the following CDRs:
- i. CDR1 having the amino acid sequence of SEQ ID NO:12;
- ii. CDR2 having the amino acid sequence of SEQ ID NO:13;
- and
- iii. CDR3 having the amino acid sequence of SEQ ID NO:14;
- and
- a light chain variable region comprising the following CDRs:
- i. CDR1 having the amino acid sequence of SEQ ID NO:15;
- ii. CDR2 having the amino acid sequence of SEQ ID NO:16;
- and
- iii. CDR3 having the amino acid sequence of SEQ ID NO:17;
- wherein the antibody binds to human α-synuclein (SEQ ID NO:1).
An isolated antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:18 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:19, wherein the antibody binds to human α-synuclein (SEQ ID NO:1).
An isolated antibody comprising a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:20 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:21, wherein the antibody binds to human α-synuclein (SEQ ID NO:1).
An isolated antibody comprising two heavy chains and two light chains, wherein each of the heavy chains comprises the amino acid sequence set forth in SEQ ID NO:20 and each of the light chains comprises the amino acid sequence set forth in SEQ ID NO:21, wherein the antibody binds to human α-synuclein (SEQ ID NO:1).
Dependencies are inferred from the claim text.